Discussions with leaders: David Mankoff, associate editor for JNM, talked with Chi Van Dang and Elizabeth Jaffee about their leadership in guiding national priorities for translational cancer research and perspectives on the roles of molecular imaging and theranostics.
Page 637
Clinical fluorescence imaging guideline: Heeman and colleagues discuss the elements of a uniform fluorescence imaging protocol to match emerging clinical needs and ensure consistent study designs and reliable data collection in clinical trials.
Page 640
Total-body PET and the future: Pantel and colleagues summarize the current state of the art in total-body PET imaging and explore probable long-term impacts in the clinical and research settings.
Page 646
Radiotracers in cardiovascular imaging: Stendahl and colleagues provide the first in a 2-part series, here examining technical considerations in cardiovascular radiotracer development and emerging radiotracers for perfusion and neuronal imaging.
Page 649
Signaling that drives 18F-FDG PET: Salas and Clark review recent studies identifying new proteins and signaling pathways that drive glucose consumption in cancer and discuss current limitations to understanding of the associated mechanisms.
Page 659
11C-Methionine PET in pediatric glioma: Bag and colleagues assess whether 11C-methionine PET detection of functionally active tumors is useful for further evaluating MRI changes related to tumor recurrence during routine surveillance of pediatric high-grade gliomas.
Page 664
Fluorescence assessment of lymph nodes: Vonk and colleagues investigate the postoperative use of epidermal growth factor receptor–targeted fluorescence molecular imaging to discriminate between tumor-positive and -negative lymph nodes in patients with oral cancer.
Page 672
90Y radioembolization in NETs: Schaarschmidt and colleagues analyze the use of 90Y radioembolization in neuroendocrine tumor patients with hepatic metastases and look at potential applications in a multimodal treatment approach.
Page 679
89Zr-Durvalumab PET in NSCLC: Smit and colleagues detail the safety and efficacy of PET/CT with this 89Zr-labeled anti–programmed death ligand 1 monoclonal antibody in advanced-stage non–small cell lung cancer and explore correlations between PD-L1 immunohistochemistry and treatment response.
Page 686
18F-FES biodistribution in ER+ breast cancer: Iqbal and colleagues describe the biodistribution of 18F-FES and altered tracer kinetics in patients with metastatic estrogen receptor–positive breast cancer undergoing treatment with rintodestrant, a novel selective ER degrader.
Page 694
Utility of ER imaging: Okazawa offers perspective on the usefulness and challenges of 18F-FES imaging assessment of estrogen receptor expression and previews an article in this issue of JNM on the promise of 18F-4FMFES, a new homolog.
Page 700
18F-4FMFES and 18F-FDG PET: Paquette and colleagues report on the preliminary results of a phase II clinical trial investigating the use of the estrogen receptor–targeting PET tracer 18F-4FMFES and 18F-FDG PET in endometrial cancers.
Page 702
18F-FLT in early soft-tissue sarcoma: Crompton and colleagues evaluate 18F-FLT PET/CT as an early prognostic imaging biomarker of long-term overall and disease-specific survival in soft-tissue sarcoma patients treated with neoadjuvant therapy and surgical resection.
Page 708
Second cancers on 18F-fluciclovine PET: Parihar and colleagues document the detection rate of 18F-fluciclovine PET/CT for incidental second primary neoplasms in patients with prostate cancer.
Page 713
CD8 PET with 89Zr-Df-IAB22M2C: Farwell and colleagues report on a study optimizing conditions for performing CD8 PET imaging with 89Zr-Df-IAB22M2C and assess the safety and efficacy of this method for visualizing whole-body CD8+ leukocyte biodistribution.
Page 720
90Y-FAPI therapy for advanced cancer: Ferdinandus and colleagues discuss initial experience with the feasibility and safety of this fibroblast-activation protein–targeted radioligand therapy in extensively pretreated patients with solid tumors.
Page 727
18F-DCFPyL, 18F-FDG, and 18F-NaF in metastatic PCa: Fourquet and colleagues compare the performance of these 18F-labeled PET/CT agents in lesion detection, agreement, and associations with diagnostic factors in a prospective cohort of men with metastatic prostate cancer.
Page 735
Specific activity and 18F-rhPSMA-7.3 uptake: Langbein and colleagues investigate whether the time between synthesis and injection of this PSMA ligand and resulting decrease in specific activity affect normal organ and tumor uptake in patients with prostate cancer.
Page 742
68Ga-PSMA total MTV repeatability: Seifert and colleagues explore the repeatability of a semiautomatic approach to derive total molecular tumor volume and related metrics from 68Ga-PSMA-HBED-CC PET in men with prostate cancer.
Page 746
Pentixather biokinetics and dosimetry: Hänscheid and colleagues analyze the biokinetics and dosimetry of 177Lu-pentixather and 90Y-pentixather targeting the chemokine receptor 4 in radiopeptide therapy for hematologic neoplasms.
Page 754
Modeling DSBs for PRRT: Tamborino and colleagues build a simulation framework to evaluate the number of early DNA double-strand breaks induced by in vitro targeted peptide-receptor radionuclide therapy with 177Lu-DOTATATE.
Page 761
Ketosis and myocardial glucose uptake: Selvaraj and colleagues compare the performance of exogenous ketone administration with a ketogenic diet regimen to achieve myocardial glucose suppression and look at predictors of such suppression.
Page 770
Brain stem hypermetabolism in ALS/FTD: Zanovello and colleagues use 18F-FDG PET/MR imaging to investigate spatial patterns of metabolic changes in the brain stem and cervical spinal cord in patients within the amyotrophic lateral sclerosis/frontotemporal dementia continuum.
Page 777
18F-FCH versus 11C-MET PET in pHPT: Mathey and colleagues compare the performances of 18F-fluorocholine and 11C-methionine for PET/CT localization of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism and negative or inconclusive 99mTc-sestamibi findings.
Page 785
GLP-1 receptor imaging: Lee and States provide commentary on an article in this issue of JNM demonstrating a stepwise approach to glucagonlike peptide-1 receptor–targeting radiotracer development from the laboratory to the clinic.
Page 792
GLP1R imaging in type 2 diabetes: Eriksson and colleagues present an optimized and simplified 68Ga-exendin4 PET/CT protocol to enable reproducible imaging of glucagonlike peptide-1 receptor in the pancreas, with potential for long-term diabetes monitoring and future therapies.
Page 794
- © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.